A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.

Start Date31 Mar 2025

Sponsor / Collaborator

Novo Nordisk A/S

NCT06691243 / Not yet recruitingPhase 2IIT

Evaluation of Semaglutide Safety and Tolerability in Adults with Cocaine Use Disorder with and Without HIV

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo.
Participants will:
* Visit the clinic once a week for semaglutide or placebo injections
* Visit the clinic once every two weeks for labwork, assessments and/or surveys

Start Date01 Mar 2025

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

NCT05646199 / Not yet recruitingPhase 2/3

The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period.
The main question it aims to answer is:
• Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS?
Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly.
The maximum duration of participation for the patients in the trial is 32 weeks.
Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

Start Date01 Mar 2025

Sponsor / Collaborator

The University of Hull

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

1,396

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Jan 2025·BRAIN RESEARCH

Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog)

Article

Author: Marinho, Thatiany S ; Mandarim-de-Lacerda, Carlos A. ; Marinho, Thatiany S. ; Aguila, Marcia B ; Fabiano, Matheus M ; Mandarim-de-Lacerda, Carlos A ; Fabiano, Matheus M. ; Aguila, Marcia B.

We studied the effect of semaglutide (glucagon-like peptide type 1 agonist) on hypothalamic pro-inflammatory genes in diet-induced obese mice. Male C57BL/6J mice were fed a control (C) or high-fat (HF) diet for 16 weeks, then divided into six groups and maintained for an additional four-week study: C, C+semaglutide (CS), C pair-feeding (CP), HF, HF+semaglutide (HFS), and HF pair-feeding (HFP).Weight gain (WG), food efficiency (FE), and plasmatic biochemistry were determined. The hypothalamus was removed and prepared for molecular analysis. Semaglutide reduced WG and FE in the HF group. High cytokines levels (tumor necrosis factor alpha, TNF alpha, monocyte chemoattractant protein 1, MCP1, and Resistin) in HF mice were reduced in HFS mice. High pro-inflammatory gene expressions were seen in HF (toll-like receptor 4, Tlr4; Mcp1; interleukin 6, Il6; Tnfa), inflammasome complex (Pirina domain-containing receptor 3, Nlrp3; Caspase 1, Il1b, Il18), and microglial activation (ionized calcium-binding adapter molecule 1, Iba1; cluster differentiation 68, Cd68; argirase 1, Arg1) but mitigated in HFS. The principal components analysis (PCA) based on these markers in a PC1 x PC2 scatterplot put HF and HFP together but far away from a cluster formed by C and HFS, indicating little significance of weight loss (HFP) but decisive action of semaglutide (HFS) in the results. In conclusion, semaglutide benefits hypothalamic pro-inflammatory genes, inflammasome complex, and microglial activation independent of the weight loss effect. Since GLP-1 receptor agonists such as semaglutide are already indicated to treat obesity and diabetes, the potential translational effects on neuroinflammation should be considered.

01 Jan 2025·JOURNAL OF AFFECTIVE DISORDERS

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Article

Author: Le, Gia Han ; Mansur, Rodrigo B. ; Rhee, Taeho Greg ; Rosenblat, Joshua D. ; McIntyre, Roger S ; Ho, Roger ; McIntyre, Roger S. ; Rosenblat, Joshua D ; Kwan, Angela T.H. ; Teopiz, Kayla M ; Wong, Sabrina ; Cao, Bing ; Kwan, Angela T H ; Teopiz, Kayla ; Mansur, Rodrigo B

INTRODUCTION:

Reports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an increased reporting odds ratio (ROR) of some measures of suicidality with semaglutide and liraglutide using the FDA Adverse Event Reporting System (FAERS). Notwithstanding the increased ROR, causality between GLP-1 RAs exposure and any aspect of suicidality is not established.

RESEARCH DESIGN AND METHODS:

The analysis herein aims to extend a previous analysis of the FAERS by evaluating the ROR for suicidality reported to the World Health Organization (WHO) Pharmacovigilance Database (VigiBase). We aimed to characterize the ROR of suicidality associated with GLP-1 RAs, as extrapolated from spontaneous reports. As per our previous report, the ROR was considered significant when the lower limit of the 95 % confidence (CI) was >1.0.

RESULTS:

We searched VigiBase reports from inception to January 2024. The RORs for suicidal ideation were significantly increased for semaglutide (5.82), liraglutide (4.03) and tirzepatide (2.25). For "depression/suicidal", the ROR was significantly increased for semaglutide (14.74) and liraglutide (5.86); and for suicidal behaviour, the ROR was significantly increased for semaglutide (6.52) and liraglutide (3.90). However, for suicide attempts, the ROR was significantly decreased for semaglutide (0.11), dulaglutide (0.075), exenatide (0.047) and liraglutide (0.15). For completed suicide, the ROR was also significantly decreased for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002) and liraglutide (0.008).

CONCLUSION:

Unlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data.

31 Dec 2024·Journal of medical economics

Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

Article

Author: Al-Omar, Hussain A ; Almodaimegh, Hind S ; Al-Harbi, Ibtisam ; Hassan, Mohamed ; Alzubaidi, Lamya M ; Al-Harbi, Bandar ; Akhtar, Omar ; Omaer, Abubker

BACKGROUND AND OBJECTIVES:

This study presents a budget impact analysis (BIA) conducted in Saudi Arabia, evaluating the cost implications of adopting semaglutide, tirzepatide, or dulaglutide in the management of type 2 diabetes mellitus (T2DM) patients. The analysis aims to assess the individual budgetary impact of these treatment options on healthcare budgets and provide insights for decision-makers.

METHODS:

A prevalence-based BIA was developed using real-world and clinical trials data. The model considered disease epidemiology, medication prices, diabetes management expenses, cardiovascular (CV) complications costs, and weight reduction savings over a 5-year time horizon. One-way and probabilistic sensitivity analyses (OWSA, PSA) were performed to assess the robustness of the results.

RESULTS:

Over a 5-year period, the cumulative budget impact for semaglutide, tirzepatide, and dulaglutide were 85,923,089 USD, 169,790,195 USD, and 94,558,356 USD, respectively. Hypothetical scenarios considering price parity between semaglutide and tirzepatide are associated with financial impacts of 85,923,091 USD and 86,475,335 USD, respectively. In the public sector, semaglutide showed the lowest incidence of 3-point major adverse CV events (3P-MACE), with tirzepatide leading in weight loss and HbA1c reduction, and dulaglutide presenting the highest 3P-MACE rates and least improvements in HbA1c and weight. A breakeven analysis suggested that tirzepatide's list price would need to be $199.91 lower than its current list price to achieve budget impact parity with semaglutide based on currently available evidence. Results from the OWSA suggested that risk reductions for CV events were key drivers of budget impact. PSA results were confirmatory of base-case analyses.

CONCLUSIONS:

CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.

1,524

News (Medical) associated with Semaglutide (Novo Nordisk)

25 Nov 2024

·www.businesswire.com

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

NATICK, Mass.--( BUSINESS WIRE )-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds , a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass. “Feedback from patients is clear; the weight must stay off. Our platform was designed specifically to help patients lose weight and keep it off,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer of Allurion. “AllurionMeds is built around safety, efficacy and, importantly, efficiency. Without affordable medications for weight loss and AI-powered behavior change, we risk bankrupting the US healthcare system.” The market opportunity for GLP-1s in the United States continues to grow, with expectations that it exceeds $100 billion with 30 million total users by 2030. 1 Recent studies are reporting, however, that 30% of patients discontinue GLP-1 drugs in the first month 2 with significant muscle mass loss 3 . These issues, combined with prices in excess of $1,300 per month 4 , will further the obesity epidemic and lead to untenable expense in the US unless access and support is improved for the millions of Americans living with this disease. Program will utilize AI to address most common GLP-1 concerns, including weight regain The AllurionMeds GLP-1 program, with support from Coach Iris, will address the most common concerns from patients looking to begin a GLP-1 program. Patients in the program will receive access to the Allurion Connected Scale and Allurion’s GLP-1 companion app. The scale measures not only weight but also muscle and bone mass to ensure that both the quantity and quality of weight loss is being monitored. Previous studies have shown that Allurion’s scale, app and lifestyle modification program in conjunction with the Allurion Balloon have helped patients lose weight while actually gaining muscle mass and helped them keep the weight off in the long-run 5,6 . “We are taking our decade-long experience of treating over 150,000 patients to launch an innovative, AI-native platform designed to solve the problems GLP-1 users face and provide a best-in-class experience,” said Dr. Gaur. “Real-world use of GLP-1s has highlighted three critical issues: poor medication adherence and wrap-around support, muscle and bone mass loss, and untenable cost to the healthcare system. AllurionMeds leverages our existing platform to address all three of these issues by providing 24/7 AI-powered coaching, monitoring of weight, muscle mass and bone mass, and offering high quality and affordable compounded semaglutide delivered at home.” AllurionMeds partnered with FDA-registered pharmacies to provide safe and financially accessible GLP-1 products available across the US Together with Coach Iris, patients will receive GLP-1 drugs that are sourced from an FDA-registered 503b facility adherent to Current Good Manufacturing Practice (CGMP) regulations. Every batch has been tested for sterility and potency, among other things, before release. “Safety and ease of use were paramount to us as we were designing AllurionMeds,” said Brian Conyer, Vice President of Digital Health at Allurion. “After careful evaluation of multiple partners, we selected pharmacies that met our high standards to create an experience that is ‘always on’ through Coach Iris. In the future, we intend to expand the types of GLP-1s available and also offer brand-name versions to provide patients with as many options as possible for their weight loss journey.” Additionally, with the launch of AllurionMeds, the company has expanded its product offerings to all 50 states in the United Sates. Previously, the company had launched the Virtual Care Suite, its B2B AI product, to obesity management clinics in the United States . “AllurionMeds further expands our presence in the United States,” said Dr. Gaur. “I believe the relationships we are creating with patients and providers in the United States could benefit future product launches by creating a foothold in the largest obesity market in the world.” To access AllurionMeds, please visit https://www.allurionmeds.com/ . About Allurion Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, Procedure-less™ intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com . Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world. Forward-Looking Statements This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the launch of the compounded GLP-1 program and the potential benefits and costs of such program, including its ability to promote long-term weight maintenance, address common GLP-1 issues and concerns, provide safe and financially accessible products, and gain a foothold in the U.S. for other products. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize its program, including the Allurion Balloon, its VCS platform, and its compounded GLP-1 program, in the United States and abroad, (ii) the timing of, and results from, our clinical studies and trials and submission of such results to regulatory authorities, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the conflict in the Middle East on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the Allurion Program, its VCS platform, and its compounded GLP-1 program (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended), Quarterly Report on Form 10-Q filed on November 13, 2024, and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations. 1 https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs 2 https://www.bcbs.com/about-us/association-news/most-americans-stop-weight-loss-drugs-before-seeing-meaningful-benefit 3 Wilding et al. NEJM . 2021;384:989-1002. 4 Hernandez et al. Obesity . 2024;32:472-475. 5 Dejeu et al. Clin. Pract. 2024;14:765-778. 6 Kosai et al. Obes Surg. 2024;34:3366-3371.

23 Nov 2024

·www.drugs.com

Taking a GLP-1 Medication? Here's Tips to Holiday Eating

SATURDAY, Nov. 23, 2024 -- So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will be served in abundance. Luckily, one expert from Baylor College of Medicine has tips on how to enjoy holiday fare while on these medications, without overdoing it. GLP-1 medications, which include Ozempic , Wegovy , Mounjaro and Zepbound , curb appetite and slow the digestion of food, so consuming large portions on these drugs can make you sick and worsens the nausea that is associated with them. What to do? Stick with small portions. “You lose the benefit of weight loss if you do not watch your diet,” said Dr. Mandeep Bajaj , a professor of medicine – endocrinology, diabetes and metabolism at Baylor. “In addition, if you are taking GLP-1 receptor agonists for treatment of diabetes, overindulging will worsen your diabetes control, and you will lose the benefit of the therapy.” Those who take GLP-1s should not stop taking them during the holidays, to avoid regaining the weight already lost. Tips to stay on track with your medication this holiday season include: For those considering starting a GLP-1 medication, Bajaj does not recommend waiting. “The whole purpose of treatment is diabetes control and weight loss in patients who are obese or overweight." he said in a Baylor news release. "There is no reason to delay it until the holidays are over, because that is the time when diabetes control worsens and you gain weight." “Patients who take these medications realize that if they follow a healthy diet of more protein and fiber, they are able to lose weight. Combining these GLP-1 receptor agonist therapies with exercise is really important to get the benefits of the treatment,” Bajaj noted. SOURCE: Baylor College of Medicine, news release, Nov. 19, 2024 Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

22 Nov 2024

·www.drugs.com

AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide

FRIDAY, Nov. 22, 2024 -- More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago. Ivy Shi, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues used data from 25,531 participants in the National Health and Nutrition Examination Survey (2015 to March 2020) to quantify the number of U.S. adults eligible for semaglutide. Eligibility criteria included: (1) diabetes; (2) weight management (body mass index [BMI] ≥30 kg/m 2 or BMI ≥27 kg/m 2 with a weight-related comorbidity [hypertension, hyperlipidemia, or history of myocardial infarction or stroke]); and (3) secondary prevention of cardiovascular disease (CVD; aged 45 years or older, BMI ≥27 kg/m 2 , and a history of myocardial infarction or stroke). The researchers found that semaglutide was indicated for an estimated 35.0 million adults for diabetes management, 129.2 million adults for weight management, and 8.9 million adults for secondary prevention of CVD. Of the 39.3 million U.S. adults eligible for semaglutide for diabetes or secondary prevention of CVD, 13.0 million were insured by Medicare and 4.7 million were insured by Medicaid. "Efforts to increase equitable uptake should be coupled with strategies to ensure that the cost of semaglutide is commensurate with the value of the health benefits it produces," the authors write. Abstract/Full Text More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHAClinical Study

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Novo Nordisk, Inc.	04 Jun 2021
Overweight	US	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	US	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	NDA/BLA	CN	Novo Nordisk A/S	26 Aug 2024
Albuminuria	Phase 3	CA	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	DE	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	NL	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	ES	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	US	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	CA	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	CO	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	DK	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	FR	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


STRIDE (NEWS \| Corporate Publications) Manual	Phase 3	Peripheral Arterial Disease	-	Ozempic (semaglutide)	ndgpzaybvu(iwubdtxcne) = xajfjxyjcn dehzrjdnjr (ogkqrghzst )	Positive	07 Nov 2024
				Placebo	ndgpzaybvu(iwubdtxcne) = bbiifgtjkk dehzrjdnjr (ogkqrghzst )
NCT06489457 (Pubmed \| Diabetes Obes Metab)	Phase 3	-	25	Semaglutide 1 mg/week	dhqvqviafx(bmxwtoujkl) = qepvcceddq vloswyfkau (kjwmyfkosj, 2 - 5.5)	Positive	07 Nov 2024
				Testosterone undecanoate 1000 mg/10-12 weeks	dhqvqviafx(bmxwtoujkl) = qnjkcehwgh vloswyfkau (kjwmyfkosj, 2 - 3.5)
NCT05564117 (OASIS 4, Obesity Week) Manual	Phase 3	Obesity	-	Oral Semaglutide 25 mg	pmyrgeypab(kyotxdcsww) = txsfpntayo vdvncaiojw (odxtwjltmy ) View more	Positive	06 Nov 2024
				Placebo	pmyrgeypab(kyotxdcsww) = zlugrszvbr vdvncaiojw (odxtwjltmy ) View more
NCT05486065 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Overweight	245	Semaglutide (Semaglutide 2.0 mg)	yhamcwlivk(wpqbolkjfm) = myapwywdab erftwvlrmm (nsdmcwenov, qycoyzqcix - karlfdtjqg) View more	-	05 Nov 2024
				Semaglutide (Semaglutide 8.0 mg)	yhamcwlivk(wpqbolkjfm) = utlqwoevhg erftwvlrmm (nsdmcwenov, xzryeqywty - skjljazqkp) View more
NCT03574597 (SELECT, PRNewswire) Manual	Phase 3	Overweight \| Obesity	-	Semaglutide 2.4 mg	mghocqoohv(bwpkbeicwk) = hnabzssqiw rvjtuybavu (cvdzvfpqva ) View more	Positive	03 Nov 2024
				Placebo	mghocqoohv(bwpkbeicwk) = maleznluhb rvjtuybavu (cvdzvfpqva ) View more
NCT04822181 (ESSENCE, Company_Website) Manual	Phase 3	Nonalcoholic Steatohepatitis	1,200	Semaglutide 2.4 mg	jkfbocxqta(ewjwkgdlys) = adpqufzbie eagxfjxjsl (zwrptmtwxs ) Met View more	Positive	01 Nov 2024
				Placebo	jkfbocxqta(ewjwkgdlys) = jendfvytyx eagxfjxjsl (zwrptmtwxs ) Met View more
NCT05064735 (STEP 9, Pubmed) Manual	Phase 3	Obesity \| Osteoarthritis, Knee	407	Semaglutide 2.4 mg	ofufrzbzrc(lcohbkybfx) = gmhwlgvjty vkelbfwsuq (ketxeahzdz ) View more	Positive	31 Oct 2024
				Placebo	ofufrzbzrc(lcohbkybfx) = tnjfmzkfpy vkelbfwsuq (ketxeahzdz ) View more
NCT05040971 (STEP 10, CTgov)	Phase 3	Prediabetic State \| Obesity	207	Semaglutide (Semaglutide 2.4 mg)	vhmcjpaczp(scolxnsuyc) = umpzswxlws xcqamyreof (joeykzdwse, jimcdaldxn - etfqveludo) View more	-	28 Oct 2024
				Semaglutide+placebo (Placebo)	vhmcjpaczp(scolxnsuyc) = zjtwhulmdk xcqamyreof (joeykzdwse, thnkvdtrrz - zzavmlmzgy) View more
Pubmed Manual	Not Applicable	Alzheimer Disease \| Diabetes Mellitus, Type 2	-	Semaglutide	aggvurndhb(gxpbjwavod): HR = 0.33 (95% CI, 0.21 - 0.51), P-Value = 0.33	Positive	24 Oct 2024
				Insulin
NCT03914326 (SOUL, Corporate Publications) Manual	Phase 3	Diabetes Mellitus, Type 2	9,650	semaglutide	qjwksemciz(eqfohrroah): Difference (%) = -14 Met	Positive	21 Oct 2024
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis